Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca is paying a Chinese biotech $185 million up front, and as much as $1.8 billion more in milestone payments, to license an experimental obesity pill.…
AstraZeneca is paying as much as $2 billion for Chinese rights to a Phase 1 experimental obesity pill, joining Novo Nordisk, Eli Lilly, and a growing list of…
Multiple clinical trial data for elecoglipron (AZD5004/ECC5004), an oral GLP-1 receptor agonist discovered by Eccogene, to be presented at ADA 2026. VISTA and…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
AstraZeneca licensed global rights (ex-China) to ECC5004 from Eccogene in November 2023, an investigational oral once-daily small-molecule GLP-1 receptor agonist for obesity, type 2 diabetes and cardiometabolic conditions. Eccogene received $185M upfront with up to $1.825B in clinical, regulatory and commercial milestones plus tiered royalties. The asset, now named elecoglipron (AZD5004), has since de-risked materially: it advanced from Phase 1 at deal signing to two completed Phase 2b trials -- VISTA in obesity/overweight (NCT06579092, n=310, completed Nov 2025) and SOLSTICE in type 2 diabetes versus semaglutide and placebo (NCT06579105, n=406, completed Dec 2025). Per AstraZeneca's FY2025 results (Feb 2026), both trials met their primary endpoints, supporting progression to Phase 3, with full Phase 2 data presented at the ADA Scientific Sessions on 8 June 2026. The readouts validate the original thesis -- a differentiated oral small-molecule entry into the GLP-1 obesity/T2D race -- though detailed efficacy magnitude vs. Eli Lilly's orforglipron and Novo's oral semaglutide remained to be benchmarked at ADA.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Eccogene (Shanghai) Co., Ltd. (this deal) | 2023 | $2.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Metabolic deals